WASF2 is overexpressed in lung adenocarcinoma [40], breast carcinoma [41], pancreatic cancer [42], hepatocellular carcinoma [43], ovarian cancer [44], and its high expression is associated with poor prognosis, treatment resistance, and metastasis. Here, WASF2 is linked to ovarian cancer.